biostudies-literatureKim DNIH/NINDSKenneth and Claudia Silverman Family FoundationChild Neurology FoundationMontel Williams FoundationNINDS NIH HHS4737https://www.ebi.ac.uk/biostudies/studies/S-EPMC9694020biostudies-literatureUnknown14(22)Vitamin D is a steroid hormone that has been widely studied as a potential therapy for multiple sclerosis and other inflammatory disorders. Pre-clinical studies have implicated vitamin D in the transcription of thousands of genes, but its influence may vary by cell type. A handful of clinical studies have failed to identify an in vivo gene expression signature when using bulk analysis of all peripheral immune cells. We hypothesized that vitamin D's gene signature would vary by immune cell type, requiring the analysis of distinct cell types. Multiple sclerosis patients (<i>n</i> = 18) were given high-dose vitamin D (10,400 IU/day) for six months as part of a prospective clinical trial (NCT01024777). We collected peripheral blood mononuclear cells from participants at baseline and again afteNutrientsPeripheral T-Cells, B-Cells, and Monocytes from Multiple Sclerosis Patients Supplemented with High-Dose Vitamin D Show Distinct Changes in Gene Expression Profiles.PMC9694020N/AScientific AwardK23 NS087151Kim DVan Haren KSachs KSteinman LBhargava PWitt EESchubert SSotirchos EMowry EMHe ZAwani ABilen BCalabresi PAfalsePeripheral T-Cells, B-Cells, and Monocytes from Multiple Sclerosis Patients Supplemented with High-Dose Vitamin D Show Distinct Changes in Gene Expression Profiles.Vitamin D is a steroid hormone that has been widely studied as a potential therapy for multiple sclerosis and other inflammatory disorders. Pre-clinical studies have implicated vitamin D in the transcription of thousands of genes, but its influence may vary by cell type. A handful of clinical studies have failed to identify an in vivo gene expression signature when using bulk analysis of all peripheral immune cells. We hypothesized that vitamin D's gene signature would vary by immune cell type, requiring the analysis of distinct cell types. Multiple sclerosis patients (<i>n</i> = 18) were given high-dose vitamin D (10,400 IU/day) for six months as part of a prospective clinical trial (NCT01024777). We collected peripheral blood mononuclear cells from participants at baseline and again afte2022-01-01T00:00:00Z2022 Nov2025-04-18T20:30:57.931Z2024-11-10T08:11:22.914ZS-EPMC96940203643242410.3390/nu14224737